Singular Genomics Systems Future Growth
Future criteria checks 2/6
Singular Genomics Systems is forecast to grow earnings and revenue by 6% and 79.7% per annum respectively while EPS is expected to grow by 16.6% per annum.
Key information
6.0%
Earnings growth rate
16.6%
EPS growth rate
| Life Sciences earnings growth | 15.9% |
| Revenue growth rate | 79.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 36 | -79 | N/A | N/A | 2 |
| 12/31/2025 | 14 | -82 | N/A | N/A | 2 |
| 12/31/2024 | 2 | -88 | N/A | N/A | 2 |
| 12/31/2023 | 3 | -95 | -75 | -74 | N/A |
| 9/30/2023 | 3 | -93 | -77 | -75 | N/A |
| 6/30/2023 | 2 | -94 | -83 | -80 | N/A |
| 3/31/2023 | 2 | -93 | -90 | -85 | N/A |
| 12/31/2022 | 1 | -91 | -93 | -87 | N/A |
| 9/30/2022 | N/A | -90 | -89 | -83 | N/A |
| 6/30/2022 | N/A | -83 | -79 | -72 | N/A |
| 3/31/2022 | N/A | -97 | -68 | -62 | N/A |
| 12/31/2021 | N/A | -99 | -57 | -52 | N/A |
| 9/30/2021 | N/A | -87 | -46 | -43 | N/A |
| 6/30/2021 | N/A | -77 | -41 | -39 | N/A |
| 3/31/2021 | N/A | -47 | -31 | -29 | N/A |
| 12/31/2020 | N/A | -28 | -26 | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OMIC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OMIC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OMIC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OMIC's revenue (79.7% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: OMIC's revenue (79.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OMIC's Return on Equity is forecast to be high in 3 years time